BTBD14A Activators
BTBD14A activators encompass a diverse group of compounds that enhance the protein's role in chromatin remodeling and gene regulation. Forskolin, by increasing cAMP levels, leads to the activation of protein kinase A (PKA), which is known to phosphorylate various substrates. Such phosphorylation events can indirectly increase the functional activity of BTBD14A, as PKA-mediated changes in transcriptional regulators influence chromatin structure, where BTBD14A functions. Similarly, IBMX, through its inhibition of phosphodiesterases, elevates cAMP levels, sustaining PKA activity that may promote BTBD14A's engagement with chromatin. Direct activation of Epac by its specific activator, leading to Rap1 activation, represents another pathway through which chromatin modification processes can be influenced, thereby enhancing BTBD14A's activity.
Additionally, JQ1, by inhibiting the interaction of BET proteins with chromatin, potentially creates a more permissive environment for BTBD14A's chromatin remodeling activity. Histone deacetylase inhibitors, such as Trichostatin A, MS-275, and SAHA, induce a more open chromatin conformation, which could facilitate BTBD14A in exerting its regulatory functions on gene expression. The demethylating agent 5-Azacytidine and DNA methyltransferase inhibitor RG108 alter DNA methylation patterns, possibly creating a chromatin landscape more amenable to BTBD14A's action. Inhibitors targeting histone methyltransferases, like BIX-01294 against G9a, (R)-PFI-2 against SETD7, and UNC0638 against G9a and GLP, shift the histone modification patterns. These changes in the epigenetic marks are conducive to the remodeling activities of BTBD14A, enhancing its ability to modulate chromatin structure and, consequently, gene expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels, which in turn activate PKA. PKA can phosphorylate transcriptional regulators, which may enhance the functional activity of BTBD14A in chromatin remodeling. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, leading to an increase in cAMP levels and subsequent activation of PKA. PKA, by phosphorylating factors involved in chromatin dynamics, could indirectly increase BTBD14A activity. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a BET bromodomain inhibitor which displaces BET proteins from chromatin, leading to altered transcriptional dynamics. This may enhance the role of BTBD14A in chromatin remodeling by changing the chromatin landscape. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs), leading to a more open chromatin structure. This could potentially enhance the accessibility for BTBD14A to chromatin, increasing its functional activity. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine inhibits DNA methyltransferases, leading to reduced DNA methylation and altered chromatin structure, potentially enhancing the chromatin remodeling function of BTBD14A. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 is a selective HDAC inhibitor, resulting in hyperacetylated chromatin and potentially facilitating BTBD14A's engagement with chromatin, enhancing its activity in gene regulation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
SAHA, another HDAC inhibitor, leads to an open chromatin state which may favor BTBD14A-mediated chromatin remodeling processes, thereby enhancing its activity. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108 is a DNA methyltransferase inhibitor that results in demethylation of DNA, impacting chromatin structure and potentially enhancing BTBD14A's functional activity in chromatin remodeling. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $37.00 $112.00 $408.00 | ||
BIX-01294 is a G9a histone methyltransferase inhibitor which leads to reduced histone methylation, a process that could enhance BTBD14A's access to chromatin, potentially increasing its activity in gene regulation. | ||||||
UNC0638 | 1255580-76-7 | sc-397012 | 10 mg | $315.00 | ||
UNC0638 is an inhibitor of the histone methyltransferase G9a and GLP, affecting histone methylation status and potentially enhancing the chromatin remodeling activity of BTBD14A. | ||||||